Patents by Inventor Donald J. Tindall

Donald J. Tindall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for detection of metastatic prostate cancer
    Publication number: 20040259113
    Abstract: Prostrate cancer is detected by determining the presence of hK2 polypeptide of hK2 RNA in a physiological sample.
    Type: Application
    Filed: December 23, 2003
    Publication date: December 23, 2004
    Applicant: Mayo Foundation for Medical Education and Research, Hybritech Incorporated
    Inventors: Donald J. Tindall, Charles Y. F. Young
  • Method for detection of micrometastatic prostate cancer
    Publication number: 20030113743
    Abstract: Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.
    Type: Application
    Filed: April 22, 2002
    Publication date: June 19, 2003
    Applicant: Baylor College of Medicine, Hybritech Incorporated
    Inventors: Kevin M. Slawin, Donald J. Tindall, Charles Y.F. Young
  • Method for detection of micrometastatic prostate cancer
    Patent number: 6479263
    Abstract: Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: November 12, 2002
    Assignees: Baylor College of Medicine, Mayo Foundation for Medical Education and Research
    Inventors: Kevin M. Slawin, Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Abhay Kumar, Harry G. Rittenhouse, Robert L. Wolfert
  • Method for detection of breast cancer
    Patent number: 6235486
    Abstract: Breast cancer is detected by determining the presence of hK2 polypeptide or hK2 RNA in a physiological sample.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: May 22, 2001
    Assignee: Mayo Foundation for Medical Education & Research
    Inventors: Charles Y. F. Young, Donald J. Tindall, George G. Klee
  • Recombinant hK2 polypeptide
    Patent number: 6093796
    Abstract: An isolated, substantially homogenous pre-pro, pro or mature hK2 polypeptide is provided as well as biologically active variants or subunits thereof, including a biologically active variant pre-pro hK2 polypeptide having SEQ ID NO:19.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: July 25, 2000
    Assignees: Mayo Foundation for Medical Education and Research, Hybritech Incorporated
    Inventors: Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Stephen D. Mikolajczyk
  • DNA encoding hK2 variant polypeptides
    Patent number: 6013471
    Abstract: Isolated nucleic acid molecules encoding variant hK2 polypeptides and fragments thereof, as well as expression cassettes and host cells comprising said nucleic acid molecules, are provided. Also provided is a method to express a nucleic acid molecule encoding a variant hK2 polypeptide.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: January 11, 2000
    Assignees: Hybritech Incorporated, Mayo Foundation for Medical Education and Research
    Inventors: Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Abhay Kumar
  • Antibodies specific for human prostate glandular kallkrein
    Patent number: 5516639
    Abstract: The present invention provides an isolated preparation of monoclonal or polyclonal antibodies which react specifically with human prostate-specific glandular kallikrein (hK2), but which do not cross-react with human prostate-specific antigen (PSA), as well as immunogenic hK2 antigens useful to provide such antibodies.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: May 14, 1996
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Donald J. Tindall, Charles Y. F. Young, George G. Klee
  • Urogenital sinus derived growth inhibitory factor
    Patent number: 5196334
    Abstract: A process is provided for purifying Urogenital Sinus Derived Growth Inhibitory Factor (UGIF) from embryonic tissue which comprises chromatographing medium from cultures of embryonic tissue derived from the urogenital sinus by gel filtration chromotography. Further purification by reverse phase high pressure liquid chromotography is also demonstrated. The UGIF is obtained in 70-fold to 8000-fold purification over the conditioned medium. A UGIF composition of matter is also provided.
    Type: Grant
    Filed: September 2, 1988
    Date of Patent: March 23, 1993
    Assignee: Baylor College of Medicine
    Inventors: David R. Rowley, Donald J. Tindall, Sr.
  • 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-androstano[3,2-c]pyrazole 17-methyl ether
    Patent number: 4585765
    Abstract: 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstano[3,2-c]pyrazole 17-methyl ether is a very potent reversible male contraceptive which has a very low degree of androgenic side effects. Upon cessation of administration fertility promptly returns.
    Type: Grant
    Filed: April 16, 1980
    Date of Patent: April 29, 1986
    Assignee: The Upjohn Company
    Inventors: Donald J. Tindall, Anthony R. Means
  • 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstano-[3,2-c]pyrazole 17-methyl ether
    Patent number: 4356175
    Abstract: 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstano[3,2-c]pyrazole 17-methyl ether is a very potent reversible male contraceptive which has a very low degree of androgenic side effects. Upon cessation of administration fertility promptly returns.
    Type: Grant
    Filed: October 10, 1978
    Date of Patent: October 26, 1982
    Assignee: The Upjohn Company
    Inventors: Donald J. Tindall, Anthony R. Means
  • Reversible male contraception
    Patent number: 4252798
    Abstract: Various steroids which have a high affinity for rat ABP (androgen binding protein) and a low affinity for rat AR (androgen receptor) have been found to be useful as male contraceptives. Upon cessation of administration of the steroids of the present invention the male promptly regains normal fertility.
    Type: Grant
    Filed: February 14, 1980
    Date of Patent: February 24, 1981
    Assignee: The Upjohn Company
    Inventor: Donald J. Tindall